Huntsville-based Diatherix Eurofins has developed a test for the SARS-CoV-2 virus, the cause of the COVID-19 respiratory infection, as part of its proprietary respiratory testing portfolio.
The new COVID-19 Panel includes the SARS-CoV-2 virus along with five bacterial pathogens that are known to be more prevalent and relevant to the severity of complications in both upper and lower respiratory tract infections. To simplify collection for healthcare workers, Diatherix can analyze nasopharyngeal specimen collection methods and sputum specimen swabs.
The company aims to return test results back to clinicians the same day it receives the specimen.
With Diatherix’s COVID-19 Panel, clinicians will gain the ability to confirm the presence of SARS-CoV-2 along with additional diagnostic information of synergistic bacteria. These bacterial pathogens include Chlamydophila pneumoniae, Haemophilus influenzae, including Haemophilus influenzae (type B), Moraxella catarrhalis, Mycoplasma pneumoniae, and Streptococcus pneumoniae, which are also known to exacerbate the recovery for high-risk patients.
The testing solution will be available through other Eurofins U.S. clinical laboratories as well, including Boston Heart Diagnostics and EGL Genetics. At this time, Diatherix Eurofins cannot accept specimens from the state of New York.
More information can be found here.
Eurofins Scientific, parent company of Diatherix, is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience services.
